Company: HURA
Filing Date: 2025-12-10
Form Type: 424B5
Source: 0001193125-25-313799
Chunk: 20

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-12-10
Form: 424B5
Chunk 20
---
% of the aggregate number of shares of Common Stock (or Common Stock equivalents, if applicable) issued in this offering at an exercise price of $2.0625 (equal to 125% of the offering price of the securities). The Placement Agent Warrants will expire five years from the commencement of sales of the offering. The Placement Agent Warrants are registered by the registration statement of which this prospectus supplement is a part. The form of the Placement Agent Warrant is included as an exhibit to the Company’s Current Report on Form 8-Krelated to this offering and is incorporated by reference herein. The following table shows the offering price per share of Common Stock and accompanying Warrants and total placement agent fees we will pay to the placement agents in connection with the sale of securities pursuant to this prospectus supplement and the accompanying prospectus.

|                                  |     | Per Share and 
 Accompanying  
 Warrants      |        |     | Total |               |
|:---------------------------------|:----|:--------------|-------:|:----|:------|--------------:|
| Offering price                   |     | $             |   1.65 |     | $     | 15,612,997.95 |
| Placement Agent Fees             |     | $             | 0.0785 |     | $     |    742,909.88 |
| Proceeds, before expenses, to us |     | $             | 1.5715 |     | $     | 14,870,088.07 |

S-16

After deducting certain fees and expenses due to the placement agents and our estimated offering expenses, we expect the net proceeds from this offering to be approximately $14.4 million. The estimated offering expenses payable by us, excluding the placement agents fees and expenses, is approximately $460,000, which includes approximately $260,000 that we have agreed to pay the Paulson Investment Company, LLC, for acting as financial advisor in connection with this offering. Tail We have also agreed to pay Wainwright a tail fee equal to both the cash and warrant compensation in this offering, if any investor who had back and forth correspondence with Wainwright or introduced to us by Wainwright provides us with capital in any public or private offering or other financing or capital raising transaction during the nine-month period following expiration or termination of our engagement with Wainwright upon the final closing of this offering. Regulation M The placement agents may be deemed to be underwriters within the meaning of Section 2(a